Rapport Therapeutics issues $172.5 million in 2.25% convertible senior notes due 2032
RAPP•Rapport Therapeutics issued $172.5 million of convertible senior notes, raising approximately $166.8 million net. The notes carry 2.25% annual interest, mature December 1, 2032, and have an initial conversion price of approximately $26.775 per share.
1. Note offering
Rapport Therapeutics issued $172.5 million of convertible senior notes on October 30, 2026, raising approximately $166.8 million net. The general unsecured notes carry a 2.25% annual interest rate and mature December 1, 2032.
2. Conversion and proceeds
Conversions will settle in common stock at an initial conversion price of approximately $26.775 per share, subject to adjustments. The company plans to use the proceeds primarily for RAP-219 clinical trials, other research and development, working capital and general corporate purposes.
